文献速递主动脉疾病内脏/肾动脉与血管畸形

内脏缺血对开窗/分支腔内修复胸腹主动脉瘤患者的临床影响

The Clinical Impact of Splanchnic Ischemia on Patients Affected by Thoracoabdominal Aortic Aneurysms Treated with Fenestrated and Branched Endografts.
PubMed 文献 · Ann Vasc Surg · 2019-04-19

本研究前瞻性纳入2010至2015年接受开窗/分支腔内修复(FB-EVAR)的胸腹主动脉瘤(TAAA)患者36例,评估围术期CT血管造影可见的内脏缺血病变(SIL)的发生率及其临床影响。结果显示33%患者出现SIL,主要为栓塞性,SIL与术后24小时CRP和胆红素升高相关,肠系膜上动脉SIL与30天死亡率升高相关。

要点

  • FB-EVAR术后SIL发生率为33%,主要原因为栓塞(79%)。
  • SIL与术后24小时CRP和胆红素升高相关,但30天内实验室异常多无临床后果。
  • 肠系膜上动脉SIL与30天死亡率升高相关(50% vs 7%,P=0.002)。

核心结论

  • FB-EVAR治疗TAAA后SIL常见,主要源于栓塞,多数实验室改变30天内消失,但肠系膜上动脉SIL与30天死亡率升高相关。

研究设计与样本

  • 前瞻性队列研究,纳入2010至2015年接受FB-EVAR的TAAA患者36例(男性78%,年龄73±7岁),其中I-III型27例(75%),IV型9例(25%),共涉及127条目标内脏血管。

主要发现

  • 12例(33%)患者发生14处SIL:胰腺4处(29%)、脾3处(21%)、肠2处(14%)、肾5处(36%)。
  • SIL原因:栓塞79%,血栓21%。
  • 术后24小时胰腺、肝脏、肾脏功能恶化分别发生于16例(44%)、16例(44%)、9例(25%)。
  • SIL与24小时CRP升高(17.9±0.4 vs. 9.9±9.0 mg/dL;P=0.03)和胆红素升高(1.2±2.3 vs. 1.0±0.5 mg/dL;P=0.02)相关。
  • 肠系膜上动脉SIL与30天死亡率升高相关(50% vs. 7%;P=0.002)。

关键数值与推荐

  • SIL定义为围术期CT血管造影可见的内脏缺血病变。
  • 实验室内脏功能恶化定义为较基线下降≥25%。

临床怎么用

  • FB-EVAR术后应监测CRP、胆红素、活化部分凝血活酶时间和淀粉酶等实验室指标,警惕SIL发生。
  • 对于肠系膜上动脉SIL需密切观察,因其与30天死亡率升高相关。

局限性

  • 样本量较小(36例),单中心前瞻性研究,未发现临床、形态或手术预测因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fenestrated/branched endografts for aortic repair (FB-EVAR) are valid options to treat thoracoabdominal aortic aneurysms (TAAAs). Successful repair requires manipulation of target visceral vessels (TVVs) with possible splanchnic ischemia. The aim of the study was to evaluate the clinical impact of splanchnic ischemia occurring in FB-EVAR for TAAA. METHODS: Between 2010 and 2015, patients with TAAAs undergoing FB-EVAR were prospectively enrolled. Clinical, morphological, procedural, and 30-day data were evaluated. Splanchnic ischemia was defined as the presence of splanchnic ischemic lesions (SILs) visible at perioperative computed tomography angiography. Preoperative, postoperative, and 30-day hepatic/pancreatic/renal laboratory functions were analyzed. End points were incidence of SILs, laboratory splanchnic functions worsening (≥25% of baseline), and presence of related clinical/morphological and procedural risk factors. RESULTS: Thirty-six patients (male: 78%; age: 73 ± 7 years) with 27 (75%) type I-III and 9 (25%) type IV TAAA who underwent FB-EVAR for a total of 127 TVV (branches: 47-60%; fenestrations: 53-67%). Fourteen SILs occurred in 12 (33%) patients: 4 (29%) in pancreas, 3 (21%) in spleen, 2 (14%) in bowel, 5 (36%) in kidney. The cause was embolic in 79% and thrombotic in 21%. No preoperative clinical/morphological data or procedural data were correlated with SIL. Pancreatic, hepatic, or renal function worsening occurred at 24 hr in 16 (44%), 16 (44%), and 9 (25%) cases, respectively. Overall, SILs were associated with increased values of C-reactive protein (CRP) (17.9 ± 0.4 vs. 9.9 ± 9.0 mg/dL; P = 0.03) and bilirubin (1.2 ± 2.3 vs. 1.0 ± 0.5 mg/dL; P = 0.02) at 24 hr. Specifically, SIL of the celiac trunk and superior mesenteric and renal arteries' parenchyma were associated with the significant laboratory function changes 24 hr. SIL of the superior mesenteric artery was associated with increased 30-day mortality (50% vs. 7 %; P = 0.002). Pancreatic, hepatic, or renal function worsening occurred at 30 days in 2 (6%), 0 (0%), and 4 (12%) cases, with similar laboratory tests in patients with and without SIL. CONCLUSIONS: SIL can be frequently detected after FB-EVAR for TAAA and appears mainly of embolic origin. No clinical, morphological, or procedural predictors could be identified in our series. Postoperative laboratory changes of CRP, bilirubin, activated partial thromboplastin time, and amylases are associated with SIL but disappear without clinical consequences within 30 days. However, SIL occurring in the superior mesenteric artery are associated with an increased 30-day mortality.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Gallitto E, Faggioli G, Ancetti S, et al. The Clinical Impact of Splanchnic Ischemia on Patients Affected by Thoracoabdominal Aortic Aneurysms Treated with Fenestrated and Branched Endografts. Ann Vasc Surg. 2019. PMID: 31009717. doi:10.1016/j.avsg.2019.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。